157 related articles for article (PubMed ID: 24155829)
21. The value of irbesartan in the management of hypertension.
Bramlage P; Durand-Zaleski I; Desai N; Pirk O; Hacker C
Expert Opin Pharmacother; 2009 Aug; 10(11):1817-31. PubMed ID: 19601700
[TBL] [Abstract][Full Text] [Related]
22. Comparative cost effectiveness of angiotensin II receptor blockers in a US managed care setting: olmesartan medoxomil compared with losartan, valsartan, and irbesartan.
Simons WR
Pharmacoeconomics; 2003; 21(1):61-74. PubMed ID: 12484804
[TBL] [Abstract][Full Text] [Related]
23. Identification and determination of selected angiotensin II receptor antagonist group drugs by HPLC method.
Czerwińska K; Mazurek AP
Acta Pol Pharm; 2011; 68(6):831-7. PubMed ID: 22125946
[TBL] [Abstract][Full Text] [Related]
24. Cardiovascular outcomes in high-risk patients without heart failure treated with ARBs: a systematic review and meta-analysis.
Al Khalaf MM; Thalib L; Doi SA
Am J Cardiovasc Drugs; 2009; 9(1):29-43. PubMed ID: 19178130
[TBL] [Abstract][Full Text] [Related]
25. Drug Interactions with Angiotensin Receptor Blockers: Role of Human Cytochromes P450.
Yang R; Luo Z; Liu Y; Sun M; Zheng L; Chen Y; Li Y; Wang H; Chen L; Wu M; Zhao H
Curr Drug Metab; 2016; 17(7):681-91. PubMed ID: 27216792
[TBL] [Abstract][Full Text] [Related]
26. Angiotensin II receptor blockers for the treatment of heart failure: a class effect?
Hudson M; Humphries K; Tu JV; Behlouli H; Sheppard R; Pilote L
Pharmacotherapy; 2007 Apr; 27(4):526-34. PubMed ID: 17381379
[TBL] [Abstract][Full Text] [Related]
27. Developing drug formularies for the "National Medical Holding" JSC.
Akhmadyar NS; Khairulin BE; Amangeldy-Kyzy S; Ospanov MA
Int J Risk Saf Med; 2015; 27 Suppl 1():S51-2. PubMed ID: 26639709
[TBL] [Abstract][Full Text] [Related]
28. A review of the use of angiotensin receptor blockers for the prevention of cardiovascular events in patients with essential hypertension without compelling indications.
Zaiken K; Hudd TR; Cheng JW
Ann Pharmacother; 2013 May; 47(5):686-93. PubMed ID: 23585649
[TBL] [Abstract][Full Text] [Related]
29. A systematic comparison of the properties of clinically used angiotensin II type 1 receptor antagonists.
Michel MC; Foster C; Brunner HR; Liu L
Pharmacol Rev; 2013 Apr; 65(2):809-48. PubMed ID: 23487168
[TBL] [Abstract][Full Text] [Related]
30. The System of Objectified Judgement Analysis (SOJA). A tool in rational drug selection for formulary inclusion.
Janknegt R; Steenhoek A
Drugs; 1997 Apr; 53(4):550-62. PubMed ID: 9098659
[TBL] [Abstract][Full Text] [Related]
31. Examining the association of olmesartan and other angiotensin receptor blockers with overall and cause-specific mortality.
Lin JW; Chang CH; Caffrey JL; Wu LC; Lai MS
Hypertension; 2014 May; 63(5):968-76. PubMed ID: 24516110
[TBL] [Abstract][Full Text] [Related]
32. Newly emerging pharmacologic differences in angiotensin II receptor blockers.
Oparil S
Am J Hypertens; 2000 Jan; 13(1 Pt 2):18S-24S. PubMed ID: 10678284
[TBL] [Abstract][Full Text] [Related]
33. Common angiotensin receptor blockers may directly modulate the immune system via VDR, PPAR and CCR2b.
Marshall TG; Lee RE; Marshall FE
Theor Biol Med Model; 2006 Jan; 3():1. PubMed ID: 16403216
[TBL] [Abstract][Full Text] [Related]
34. Switch strategies in the management of hypertension: a cost minimisation analysis of angiotensin receptor blocker based regimen.
Belsey JD
Curr Med Res Opin; 2008 Feb; 24(2):581-9. PubMed ID: 18198012
[TBL] [Abstract][Full Text] [Related]
35. Impact of Modified System of Objectified Judgement Analysis (SOJA) methodology on prescribing costs of ACE inhibitors.
Alabbadi I; Crealey G; Scott M; Baird S; Trouton T; Mairs J; McElnay J
Clin Drug Investig; 2006; 26(9):485-94. PubMed ID: 17163281
[TBL] [Abstract][Full Text] [Related]
36. Effects of telmisartan, irbesartan, valsartan, candesartan, and losartan on cancers in 15 trials enrolling 138,769 individuals.
ARB Trialists Collaboration
J Hypertens; 2011 Apr; 29(4):623-35. PubMed ID: 21358417
[TBL] [Abstract][Full Text] [Related]
37. Retrospective analysis of real-world efficacy of angiotensin receptor blockers versus other classes of antihypertensive agents in blood pressure management.
Petrella R; Michailidis P
Clin Ther; 2011 Sep; 33(9):1190-203. PubMed ID: 21885126
[TBL] [Abstract][Full Text] [Related]
38. Towards a Transparent, Credible, Evidence-Based Decision-Making Process of New Drug Listing on the Hong Kong Hospital Authority Drug Formulary: Challenges and Suggestions.
Wong CKH; Wu O; Cheung BMY
Appl Health Econ Health Policy; 2018 Feb; 16(1):5-14. PubMed ID: 28702874
[TBL] [Abstract][Full Text] [Related]
39. Interaction of angiotensin receptor type 1 blockers with ATP-binding cassette transporters.
Weiss J; Sauer A; Divac N; Herzog M; Schwedhelm E; Böger RH; Haefeli WE; Benndorf RA
Biopharm Drug Dispos; 2010 Mar; 31(2-3):150-61. PubMed ID: 20222053
[TBL] [Abstract][Full Text] [Related]
40. Differential pharmacology and benefit/risk of azilsartan compared to other sartans.
Kurtz TW; Kajiya T
Vasc Health Risk Manag; 2012; 8():133-43. PubMed ID: 22399858
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
